The Role of Incretins in Bone Remodeling in Humans (INCREMOS)

University Hospital, Angers

Status: Terminated

Conditions: Osteoporosis; Incretins; Healthy; Bone Remodeling

Treatments: Other: blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT03966261

2018-A01632-53

Details and patient eligibility

About

The role of incretins (GIP and GLP-1) on cells and bone tissue has been shown in cellular and animal studies. In humans, the role of these hormones is mainly studied in the pathophysiology of diabetes, their effect on bone is unknown. The serum incretin concentration is low and increases rapidly after a meal. This increase is brief, incretins being rapidly degraded by dipeptidylpeptidase 4 (DPP-4). The dosage of these hormones is complex and the basal "normal" serum concentrations and after feeding in healthy subjects are unknown. Before any study on the effect of incretins on bone remodeling in humans, it is necessary to establish physiological concentrations of incretins in healthy subjects.

The aim of this study is to estimate physiological concentrations of incretins in healthy subject.

Enrollment: 104 patients

Sex: All

Ages: 30 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy women and men

Exclusion criteria

• known osteoporosis
• osteoporotic fracture
• tobacco
• alcohol : > 2 glasses/day
• type 1 and type 2 diabetes
• BMI < 19kg/m² or > 30kg/m²
• heart failure, kidney failure
• cancer
• bariatric surgery
• graft
• cirrhosis
• use in the past year : bisphosphonate, denosumab, raloxifene, teriparatide, oral or IV glucocorticoid during 3 months or more